Travere Therapeutics Is Maintained at Buy by Guggenheim
Ratings actions from Benzinga: GMT) Travere Therapeutics Price Target Raised to $89.00/Share From $75.00 by GuggenheimRatings actions from Benzinga
Ratings actions from Benzinga: GMT) Travere Therapeutics Price Target Raised to $89.00/Share From $75.00 by GuggenheimRatings actions from Benzinga